الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 95 |  |  |
| | | from | 95 | | |
Abstract
Hepatocellular Carcinoma (HCC) is an inoperable disease with very poor prognosis for the majority of patients mainly due to late diagnosis. Previous reports have identified several biomarkers for HCC; however the effectiveness of these markers is not fully assessed. Current screening methods for HCC in high risk patients depend on alphafetoprotein (AFP), the most important and widely used marker for HCC, and ultrasound of the liver. Neither test is sensitive or specific enough for early detection. Thus, there is an urgent need to identify novel biomarkers for the early detection of HCC which may provide hope to improve the treatment outcome.